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Abstract
Thus far, only 5–15% of AML patients aged ≥60 years are cured with chemotherapy. Identification 
of patients who are less (more) likely to respond to standard chemotherapy might enable early risk 
stratification toward alternative treatment regimens. We used a next-generation sequencing panel 
of 80 cancer- and/or leukemia-associated genes to profile molecularly 423 older patients with de 
novo AML. Using variables identified in multivariable models and co-occurring mutations in 
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NPM1-mutated AML, we classified the patients into good-, intermediate- and poor-risk groups for 
complete remission (CR) attainment, disease-free (DFS) and overall survival (OS). Whereas 81% 
of good-risk patients (comprising NPM1-mutated patients harboring mutations in chromatin 
remodeling, cohesin complex, methylation-related, spliceosome, and/or RAS pathway genes, 
FLT3-TKD, and/or patients without FLT3-ITD) achieved a CR, only 32% of poor-risk patients 
(with U2AF1, WT1 mutations and/or complex karyotype) did. Intermediate-risk patients had a 
50% CR rate. Similarly, using NPM1 co-mutation patterns and SF1 mutation status, we identified 
patients with favorable DFS and OS 3-year rates of 46% and 45%, respectively. Patients with 
adverse genetic features had DFS and OS rates of only 2% and 4%. We show that application of 
our proposed criteria may refine the 2017 European LeukemiaNet classification for older patients 
treated with chemotherapy.
INTRODUCTION
Only five decades ago, acute myeloid leukemia (AML) was considered incurable. Although 
the introduction of cytarabine and daunorubicin in the 1960s and 1970s, respectively, 
changed the fate of many younger AML patients, intensive approaches to treat the AML of 
older patients (aged ≥60 years) were limited. Despite changes in treatment regimens, the 
patient’s age (and the corresponding treatment intensity) remains one of the most important 
prognostic factors in AML. Whereas approximately 40% of adult patients under the age of 
60 years will be cured of their leukemia, only 5 to 15% of AML patients who are ≥60 years 
will.1,2
Recently, large studies assessing biologic and prognostic significance of multiple gene 
mutations have increased our understanding of the molecular features of AML.3–6 A 
combination of cytogenetic analysis and mutation testing has been integrated into the 
classification and risk assessment of AML patients.2–12 However, recent advances in the 
understanding of the molecular alterations in AML pertain mostly to younger patients, who 
represent the minority of cases suffering from this disease, as almost all large studies have 
been performed in patients <60 years of age.3–5,12 As the frequencies of pretreatment 
cytogenetic abnormalities and gene mutations differ between patients aged <60 years and 
those ≥60 years of age, as does the prognostic significance of some chromosome 
abnormalities and gene mutations,13–16 AML in older patients needs to be evaluated 
separately.
The aim of our study was to determine whether specific molecular and cytogenetic features 
can be used to identify those older patients with de novo AML who are more (or less) likely 
to respond to standard cytarabine/daunorubicin-based chemotherapy. Therefore, we used a 
next-generation sequencing panel of 80 important cancer- and/or leukemia-associated genes 
to molecularly profile 423 adult patients with de novo AML aged 60 years or older, none of 
whom received allogeneic or autologous stem cell transplantation (SCT) in first complete 
remission (CR). We performed outcome analyses to assess the impact of identified gene 
mutations, cytogenetic aberrations and pretreatment clinical features on the achievement of 
CR, and disease-free (DFS) and overall survival (OS) of the patients.
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METHODS
Patients, treatment, and cytogenetic studies
Pretreatment bone marrow (BM) or peripheral blood (PB) samples containing ≥20% 
leukemic blasts suitable for next-generation sequencing were obtained from 423 adults aged 
60 years or older who were diagnosed with de novo AML (excluding acute promyelocytic 
leukemia and core-binding factor AML). Patients with secondary or treatment-related AML 
were not included. The patients were treated on Cancer and Leukemia Group B (CALGB) 
trials described in the Supplementary Information. CALGB is now a part of Alliance for 
Clinical Trials in Oncology (Alliance). No patient received SCT in first CR. Patients with 
early death (death within 30 days of starting therapy) were excluded from the study. 
Cytogenetic analyses of pretreatment BM and/or PB samples were performed by CALGB/
Alliance approved institutional laboratories, and the results were confirmed by central 
karyotype review.17 For the patient’s karyotype to be regarded as normal, at least 20 
metaphases from pretreatment BM specimens subjected to short-term (24–48 hour) cultures 
had to have been analyzed and no clonal abnormalities found. Patients provided study-
specific written informed consent to participate in treatment studies (see Supplementary 
Information), CALGB 8461 (cytogenetic studies), CALGB 9665 (leukemia tissue bank) and 
CALGB 20202 (molecular studies), which involved collection of pretreatment BM aspirates 
and PB samples. Study protocols were in accordance with the Declaration of Helsinki and 
approved by the institutional review boards at each center.
Statistical analysis
Definitions of the clinical endpoints–CR, DFS and OS–are provided in the Supplementary 
Information. A mutation frequency cutoff of ≥2% or at least eight patients was used for 
inclusion in the univariable outcome analyses, with P-values adjusted to control for per 
family error rate (probability of a Type I error). The families were all variables considered in 
each outcome analyses so only variables that were significant with a likelihood ratio test P-
value <0.20 adjusted from the univariable models were considered in the multivariable 
analysis (see Supplementary Information). A backward selection technique was used to 
build the final model for achievement of CR, DFS and OS.18 For time-to-event analyses, we 
calculated survival estimates using the Kaplan-Meier method,19 and compared groups using 
the Cox proportional hazard regression models.18 P-values presented in the Kaplan-Meier 
curves were determined with the log-rank test. A P-value of ≤0.05 was considered 
statistically significant. The dataset was locked on January 21, 2016. Data collection and 
statistical analyses were performed by the Alliance Statistics and Data Center.
Molecular analyses
Mononuclear cells were enriched through Ficoll-Hypaque gradient centrifugation and 
cryopreserved until use. Genomic DNA was extracted using the DNeasy Blood and Tissue 
Kit (QIAGEN, Hilden, Germany). The mutational status of 79 protein-coding genes was 
determined centrally at The Ohio State University by targeted amplicon sequencing using 
the MiSeq platform (Illumina, San Diego, CA; see Supplementary Information for details). 
In addition, CEBPA mutations were determined by Sanger sequencing,20 resulting in 80 
gene mutations analyzed in our study. Gene mutations were assigned to functional groups 
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similar to those previously described by the Cancer Genome Atlas Research Network3 as 
follows: chromatin remodeling (ASXL1, BCOR, BCORL1, EZH2 and SMARCA2), cohesin 
complex (RAD21, SMC1A, SMC3 and STAG2), kinases [AXL, FLT3 internal tandem 
duplications (FLT3-ITD), FLT3 tyrosine kinase domain mutations (FLT3-TKD), KIT and 
TYK2], methylation-related (DNMT3A, IDH1/2, and TET2), NPM1 (NPM1), RAS 
pathway (CBL, KRAS, NRAS and PTPN11), spliceosome (SF3B1, SRSF2, U2AF1 and 
ZRSR2), transcription factors (CEBPA, ETV6, GATA2, IKZF1, NOTCH1 and RUNX1) and 
tumor suppressors (PHF6, TP53 and WT1). A gene was included in the functional group if 
the mutation frequency in the total cohort was ≥2%.
RESULTS
Clinical outcome and molecular features of older patients with de novo AML
The clinical characteristics of our patient cohort are shown in Table 1. The median age was 
69 years (range, 60–85 years). Forty-one percent of our patients were female.
The outcome of our older AML patient cohort was generally poor (Table 1). Only 55% of 
patients achieved a CR following induction therapy. Of those patients who did, only 14% 
were disease-free 3 years after diagnosis. The median DFS was 7.3 months. The OS of older 
AML patients was equally poor, with a median OS of 9.4 months, and only 14% of patients 
being alive at 3 years.
We detected 1377 mutations, with a median of 3 mutations per patient (range, 0–8). The 
frequencies of detected gene mutations, gene functional groups and cytogenetic findings are 
shown in Supplementary Tables S1–S3. Only 28 genes were mutated in ≥2% of patients 
(Figure 1A), another 14 in 1–2%, and 11 genes in <1% of the patients, with 27 genes having 
no mutations (Supplementary Table S1). The most frequent were mutations in NPM1 (32% 
of patients), DNMT3A (27%), and TET2 (27%, Figure 1a). Among previously defined 
functional groups, mutations involving methylation-related genes (found in 65% of patients), 
the spliceosome (38%) and NPM1 (32%) were predominant (Figure 1b, Supplementary 
Table S2). Almost one-half of the patients in our cohort, 46%, had normal cytogenetics and 
13% harbored a complex karyotype. No other cytogenetic group comprised >10% of 
patients (Supplementary Table S3).
Impact of gene mutations and cytogenetic features on outcome
Given the generally poor treatment outcomes of older AML patients, identification of 
patients who benefit from current treatment approaches, and those who do not and hence 
should receive alternative treatment regimens instead, is of utmost importance. Thus, we 
assessed the prognostic significance of the detected gene mutations and cytogenetic features 
using multivariable analysis.
In multivariable analysis of factors associated with the achievement of CR, mutated NPM1 
(P<0.001) and the presence of a normal karyotype (P=0.03) were associated with higher 
probability of CR attainment (Table 2). Conversely, the presence of U2AF1 mutations 
(P=0.03) or WT1 mutations (P=0.01) were associated with lower CR rates.
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In multivariable analysis for DFS, the presence of NPM1 mutations (P<0.001) and SF1 
mutations (P=0.04) associated with longer DFS, with 22% of NPM1-mutated patients and 
40% of SF1-mutated patients being disease-free 3 years after diagnosis, compared with 8% 
of patients who did not harbor these mutations. The presence of FLT3-ITD (P<0.001), 
complex karyotype (P<0.001) and higher WBC counts (P=0.007) were associated with 
shorter DFS (Table 2).
In the multivariable analyses for OS, the presence of NPM1 mutations was the only feature 
associated with longer survival (P<0.001). On the other hand, FLT3-ITD (P<0.001), BCOR 
mutations (P=0.003), TP53 mutation (P=0.003), t(9;11)(p22;q23) (P=0.03) and complex 
karyotype (P=0.002) were associated with poor OS (Table 2).
The influence of coexisting mutations on the favorable prognostic impact of NPM1 
mutations
We noted that CR rates of NPM1-mutated patients varied from 50% to 95% depending on 
the presence or absence of specific mutations coexisting with mutations in the NPM1 gene 
(Figure 1c). NPM1-mutated patients who additionally harbored a mutation in the chromatin 
remodeling gene or cohesin complex gene had CR rates of 89% and 95%, respectively. 
NPM1-mutated patients with simultaneous FLT3-TKD had a CR rate of 83%, and those with 
mutations in the methylation-related or RAS pathway genes had a CR rate of 82%. In 
contrast, CR rates of NPM1-mutated patients were reduced by the presence of tumor 
suppressor mutations (to 50%), kinase mutations other than FLT3-TKD (70%), the absence 
of any methylation-related mutation (65%), or the presence of a spliceosome mutation 
(69%). Interestingly, several of the mutations that enhanced the positive prognostic impact of 
NPM1 mutations had an adverse prognostic effect in patients with wild-type NPM1 (Figure 
1d). Specifically co-occurring mutations in chromatin remodeling genes, cohesin complex 
genes, FLT3-TKD or RAS pathway genes further lowered the overall CR rate of NPM1 
wild-type patients from 44% to, respectively, 37%, 33%, 33% and 36%.
Similarly, we assessed the prognostic impact of co-occurring mutations on DFS and OS. For 
DFS, the subset analysis identified a patient group with favorable prognosis that included 
patients with the following mutation combinations: NPM1/ASXL1, NPM1/SF1, NPM1/
SMC1A or NPM1/SRSF2. These patients had a 52% chance to be alive and disease-free at 3 
years, compared with only 13% of NPM1-mutated patients without any of these co-existing 
mutations (P<0.001, Figure 2a). Similarly, patients harboring NPM1/ASXL1, NPM1/IDH2, 
NPM1/SF1 or NPM1/SRSF2 tended to fare better with respect to their OS at 3 years than 
did NPM1-mutated patients without those co-occurring mutations (47% vs 19%, P=0.009, 
Figure 2b). Of note, only IDH2 R140 mutations, but not IDH2 R172 mutations, co-occurred 
with NPM1.
Mutations in the ASXL1, IDH2, SF1, SMC1A, and SRSF2 genes are all early events, which 
have been previously implicated in clonal hematopoiesis. In our study, mutations in these 
genes frequently occurred at higher VAFs than the co-occurring NPM1 mutations (Figure 
2c). In line with previous reports,4,21 this suggests that the mutation in NPM1 is acquired 
later during hematopoiesis, thereby possibly changing the fate of the leukemic clone with 
respect to its responsiveness to therapy.
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Genetic risk stratification of older patients with AML
Using the variables identified in our univariable and multivariable models, refined by the 
consideration of the presence or absence of co-occurring mutations in NPM1-mutated AML, 
we classified the patients into good-, intermediate- and poor-risk groups with respect to their 
chance of achieving a CR following standard induction chemotherapy (Figure 3a). The 
good-risk group included NPM1-mutated patients that simultaneously harbored mutations in 
chromatin remodeling genes, the cohesin complex, FLT3-TKD, methylation-related genes, 
spliceosome genes, RAS pathway genes, and/or patients that were NPM1 mutated and did 
not harbor FLT3-ITD mutations (n=127, 30% of the patient cohort). The poor-risk group 
was characterized by patients harboring U2AF1 mutations, WT1 mutations and/or patients 
with typical complex karyotype or sole trisomy of chromosome 11 (n=95, 22% of patient 
cohort). Typical complex karyotype denotes karyotype with ≥3 abnormalities that include 
abnormalities resulting in loss of chromosome material from 5q, 7q and/or 17p; atypical 
complex karyotype therefore is one that does not contain the aforementioned abnormalities.
22,23
 The intermediate-risk group comprised all remaining patients (n=201, 48%). While 
81% (103/127) of patients in the good-risk group achieved a CR, only 32% (30/95) of 
patients in the poor-risk group attained a CR. Patients with intermediate risk (who did not 
harbor any of the positive or negative markers) had a CR rate of 50% (100/201).
However, the promising CR rate of the good-risk group did not lead to an equally good 
survival. In fact, 82% of patients in the good-risk group experienced relapse of their disease, 
which is the same as the relapse rate of the intermediate-risk group (82%), and only slightly 
better than the 93% relapse rate of the poor-risk group (data not shown).
Nonetheless, we were able to identify subsets of patients with relatively good outcome with 
respect to DFS and OS. The DFS good-risk group was comprised of NPM1-mutated patients 
that additionally harbored mutations in ASXL1, SF1, SMC1A or SRSF2, as well as SF1-
mutated patients with wild-type NPM1. Those patients exhibited DFS rates of 46% at 3 
years, compared with only 10% of the remaining patient cohort (P<0.001; Figure 3b). The 
good-risk group for OS was defined by NPM1-mutated patients that also harbored mutations 
in chromatin remodeling genes, IDH2, SF1 and/or SRSF2. They had 3-year OS rate of 45%, 
compared with an OS rate of only 11% in patients that did not harbor any of the 
aforementioned mutations (P<0.001; Figure 3c).
When specifically considering the genetic features associated with poor DFS and OS in both 
uni- and multivariable analyses [DFS: the presence of FLT3-ITD, RUNX1, TP53 or U2AF1 
mutations and/or typical or atypical complex karyotype; OS: the presence of BCOR 
mutations, FLT3-ITD, TP53, U2AF1 or WT1 mutations, t(9;11), and/or typical complex 
karyotype], we further identified a patient subset with especially poor prognosis. Only 2% of 
patients with any of these high-risk features were disease-free (Figure 3b) and only 4% were 
alive at 3 years after study enrollment (Figure 3c). The summary of our risk-stratification 
schema is depicted in Figure 3a.
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Comparison of the proposed genetic risk stratification of older patients with AML with the 
2017 European LeukemiaNet (ELN) classification
The recommendations of the European LeukemiaNet for diagnosis and management of 
AML in adults are widely accepted by physicians and investigators. A recent, updated in 
2017, version of the ELN recommendations contains a modified 3-group risk-stratification 
system based on the presence or absence of specific chromosome abnormalities and 
mutations in selected genes.9
To compare how effectively each of these classifications can stratify the patients into 
genetic-risk groups, we first applied the revised 2017 ELN classification to 397 patients in 
our cohort (the remaining 26 patients were not classifiable because of missing data). As 
Figure 4 illustrates, the modified ELN Favorable-risk groups (i.e., without CBF-AML 
patients who are not included in our study) comprised almost four times as many patients for 
DFS and three times as many patients for OS than the respective good-risk groups for DFS 
and OS in our proposed genetic classification (Figure 3b and c). Moreover, there was almost 
no separation between Kaplan-Meier curves representing the ELN Intermediate- and ELN 
Adverse-risk groups for both DFS and OS (Figure 4). The 3-year DFS rates were 25% for 
the modified ELN Favorable group, 9% for ELN Intermediate, and 3% for ELN Adverse-
risk groups. The respective 3-year OS rates were 30%, 12% and 6% (Supplementary Table 
S4). In contrast, in our risk classification 3-year DFS rates were 46% for our good-risk 
group, 17% for the intermediate-risk group, and 2% for the poor-risk group. Likewise, 3-
year OS rates of patients classified using our criteria were 45% for the good-risk, 18% for 
the intermediate-risk, and 4% for the poor-risk groups (Figure 3a).
We then applied criteria used in our proposed model to patients included in each of the 2017 
ELN risk groups. The use of our model resulted in splitting the modified 2017 ELN 
Favorable-risk group into three: the good-risk group (comprising 21 patients for DFS and 38 
for OS); the intermediate-risk group (comprising 57 and 62 patients, respectively) and the 
poor-risk group (comprising 21 patients for both DFS and OS). The 3-year DFS rates were 
52% in the good-risk group, 23% in the intermediate-risk group and 5% in the poor-risk 
group (P<0.001, Figure 5a, Supplementary Table S5). Similarly, the respective 3-year OS 
rates were 45%, 26% and 14% (P=0.009; Figure 5b; Supplementary Table S6).
Application of our model to patients included in the 2017 ELN Intermediate-risk group 
resulted in delineation of two major risk groups, the intermediate-risk group (comprising 32 
patients for DFS and 51 for OS) and poor-risk group (comprising 20 patients for DFS and 46 
for OS); for DFS two and for OS four patients were re-classified into the good-risk group. 
The 3-year DFS rates for the new intermediate-risk and poor-risk groups were 13% and 0%, 
respectively (P<0.001), and the 3-year OS rates were 20% for the intermediate-risk and 0% 
for poor-risk group (P<0.001; Figure 5c and 5d; Supplementary Tables S5 and S6).
Finally, the 2017 ELN Adverse-risk group could be divided using our criteria into the 
intermediate-risk group (comprising 14 patients for DFS and 67 for OS) and poor-risk group 
(comprising 48 patients for DFS and 108 for OS); for DFS three patients and none for OS 
were re-classified into the good-risk group. Patients in the new intermediate-risk and poor-
risk groups had the 3-year DFS rates of 7% and 2% (P=0.03) and the 3-year OS rates of 10% 
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and 4% (P=0.01), respectively (Figures 5e and 5f; Supplementary Tables S5 and S6). These 
data suggest that the use of our proposed genetic risk-stratification schema may refine the 
current 2017 ELN classification for patients aged 60 years and older treated with standard 
chemotherapy.
DISCUSSION
Despite recent advances in our understanding of the molecular background of AML,3–6 most 
of the data pertain to younger AML patients. Our study, which, to our knowledge, was 
performed on the hitherto largest cohort of AML patients aged 60 years or older who were 
analyzed with a comprehensive next-generation sequencing panel, provides important 
insights into cytogenetic and mutational features in this age group.
In line with previous studies,24–26 NPM1 mutations were the dominating marker in the older 
AML patient population. NPM1 mutations were not only the most frequent, but also the 
only mutation whose presence is associated with a higher likelihood of achieving a CR by 
patients receiving standard induction chemotherapy. NPM1 mutations also confer longer 
DFS and OS. However, we have shown that the presence or absence of additional mutations, 
such as mutations in the chromatin remodeling, cohesin complex, methylation-related and 
RAS pathway genes for CR achievement, mutations in the ASXL1, SF1, SMC1A and 
SRSF2 genes for DFS and ASXL1, IDH2, SF1 and SRSF2 mutations for OS, can influence 
the prognostic impact of NPM1 mutation. This strongly suggests that those additional genes 
need to be tested together with NPM1 in older AML patients who receive standard 
chemotherapy.
The use of mutational testing is important for the identification of the small population of 
older patients who have an excellent chance to achieve a complete remission when treated 
with standard induction chemotherapy. We have shown that patients fit for chemotherapy 
who harbored NPM1 mutations together with such co-occurring mutations as those in 
chromatin remodeling, cohesin complex, FLT3-TKD, methylation-related, RAS pathway or 
spliceosome genes, or without FLT3-ITD constitute a good-risk group whose chance of 
achieving a CR was 81%. They represented 30% of our total patient cohort. In contrast, 
patients with U2AF1 or WT1 mutations, sole trisomy 11 and/or a typical complex 
karyotype, of whom only 32% achieved a CR, should receive alternative treatment regimens, 
if possible. However, importantly, the promising CR rates of the good-risk group did not 
lead to an equally good survival. Thus, it should be considered whether alternative 
consolidation regimens would be of benefit, especially for patients who achieve an initial 
CR. Novel strategies targeting co-associated mutations (IDH1 with AG-120, and IDH2 with 
AG-221), novel immune based therapies, or non-ablative allogeneic stem cell transplant 
might be options considered for such patients. Unfortunately, we were not able to 
specifically analyze the outcome of patients who received an allogeneic transplant after 
relapse, as most CALGB/Alliance protocols did not allow an allogeneic transplant. Thus, 
patients received their allogeneic SCT off protocol, and documentation after the event was 
too limited for further analysis.
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We were also able to identify small patient subsets (approximately 10% of patients) that had 
more favorable outcomes at 3 years after enrollment (DFS, 46%; OS, 45%). Again, those 
good-risk groups were driven by the presence of NPM1 mutations, in combination with 
other mutations.
Our study further supports the notion that some recurrent cytogenetic abnormalities may 
have different prognostic significance in younger and older patients with AML. For 
example, t(9;11), which has been consistently associated with intermediate-risk group in 
younger adults,27–29 in our patient cohort conferred poor prognosis. This is consistent with 
our earlier study reporting that t(9;11) was associated with intermediate outcome only in 
AML patients younger than 60 years, whereas the outcome of patients with t(9;11) aged 60 
years or more was adverse.16 The reasons of such age difference are currently unknown.
We have also compared our proposed genetic risk stratification schema with the 2017 ELN 
classification.9 Application of the latter to our older patient cohort created a relative large 
2017 ELN modified Favorable-risk group (i.e., without patients with CBF-AML), and the 
2017 ELN Intermediate-risk and Adverse-risk groups whose DFS and OS were virtually 
identical, unlike DFS and OS of the intermediate- and poor-risk groups in our proposed 
model. Moreover, the use of our criteria to re-classify patients categorized in each of the 
2017 ELN risk groups helped to identify patient subsets with significantly different DFS and 
OS, suggesting that our proposed model may be better suited for risk stratification of 
patients aged 60 years and older who are treated with standard chemotherapy.
One of the potential limitations of our study is the use of different risk markers for each 
specific outcome endpoint, which might complicate the use of our model in clinical practice. 
However, we believe that our approach reflects the complex biology of the disease, in which 
the same cytogenetic or molecular marker, such as, for example mutated RUNX1, may be 
associated with worse DFS but not with CR attainment or OS.
In summary, our study highlights the extremely poor outcome of AML patients aged 60 
years and older with current treatment approaches. This is of special importance as older 
patients account for the majority of AML patients. We were able to identify combinations of 
mutations associated with favorable outcome in subsets of older AML patients. A limitation 
of our study is the lack of a validation cohort to confirm our findings, which is due to the 
difficulty to allocate similarly large set of older AML patients treated with standard 
chemotherapy. Thus, our encouraging findings will require validation in future prospective 
studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(a) Upper panel. Bar graph depicting the total number of mutations detected in individual 
genes (left Y-axis), as well as the percentage of patients with these mutations in our total 
patient cohort (right Y-axis). Lower panel, box and whiskers plots indicating the variant 
allele fractions (VAF), with which the mutations were detected in our AML patient set. The 
horizontal line within each box represents the median VAF, the box encloses the 25th–75th 
percentiles, and the whiskers represent the range. (b) Bar graph depicting the frequency of 
mutations in the functional groups, sorted by ascending frequencies. (c) Bar graphs showing 
the differential impact of co-occurring mutations on the positive prognostic impact of 
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NPM1. The X-axis depicts the CR rates, with the vertical line showing the median CR rate 
of all NPM1-mutated AML patients (79%). Bars depict how the wild-type (wt, bars in light 
green) or mutated (mut, bars in black) status of co-occurring mutations in the different 
functional groups affect the CR rates of NPM1-mutated patients. (d) Bar graphs showing the 
differential impact of co-occurring mutations on the CR rates of patients with wild-type 
NPM1 genes. The X-axis depicts the CR rates of NPM1 wt AML patients, with the vertical 
line showing the median CR rate of 44%. Bars depict how the wild-type (wt, bars in light 
green) or mutated (mut, bars in black) status of co-occurring mutations in the different 
functional groups affect the CR rates of NPM1 wt patients.
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Figure 2. 
(a) Disease-free survival (DFS) and (b) overall survival (OS) of NPM1-mutated patients 
stratified by the presence or absence of co-occurring mutations. The blue line represents 
patients harboring positive predictive marker in addition to the NPM1 mutation (DFS co-
mutations: ASXL1, SF1, SMC1A and SRSF2; OS co-mutations: ASXL1, IDH2, SF1 and 
SRSF2) and red line represents NPM1-mutated patients without those co-mutations. (c) 
Variant allele fractions (VAFs) of NPM1 and co-occurring mutations in individual patient 
samples. NPM1 mutations (black bars) were typically observed at lower VAFs than co-
occurring mutations (colored bars), suggesting that the NPM1 mutations are later mutational 
events.
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Figure 3. 
(a) Genetic risk stratification schema of AML patients for complete remission (CR), disease-
free survival (DFS) and overall survival (OS). (b) DFS and (c) OS based on the proposed 
risk stratification into good-, intermediate- and poor-risk groups.
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Figure 4. 
Outcome of patients classified into the Favorable-, Intermediate- and Adverse-risk groups 
using the 2017 European LeukemiaNet (ELN) criteria.9 (a) Disease-free survival and (b) 
overall survival.
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Figure 5. 
Re-classification of patients assigned into each of the 2017 European LeukemiaNet (ELN) 
risk groups into the good-, intermediate- and poor-risk groups following application of our 
proposed genetic risk stratification schema. (a) Disease-free survival and (b) overall survival 
of re-classified patients belonging to 2017 ELN Favorable-risk group. (c) Disease-free 
survival and (d) overall survival of re-classified patients belonging to 2017 ELN 
Intermediate-risk group. (e) Disease-free survival and (f) overall survival of re-classified 
patients belonging to 2017 ELN Adverse-risk group.
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Table 1
Pretreatment clinical characteristics and outcome of older patients with de novo acute myeloid leukemia
Characteristic Patients (n=423)
Age, years
  Median 69
  Range 60–85
Sex, female, n(%)
172 (41)
Race, n (%)
  White 381 (92)
  Nonwhite 33 (8)
Hemoglobin, g/dl
  Median 9.3
  Range 3.0–15.0
Platelet count, × 109/l
  Median 63
  Range 4–989
WBC count, × 109/l
  Median 21.1
  Range 0.6–450.0
Blood blasts, %
  Median 43
  Range 0–99
Bone marrow blasts, %
  Median 66
  Range 0–97
Extramedullary involvement, n (%) 85 (22)
Complete remission, n (%) 233 (55)
Disease-free survival
  Median, months 7.3
  % Disease-free at 1 year (95% CI) 33 (27–40)
  % Disease-free at 3 years (95% CI) 14 (10–19)
  % Disease-free at 5 years (95% CI) 11 (8–16)
Overall survival
  Median, months 9.4
  % Alive at 1 year (95% CI) 39 (35–44)
  % Alive at 3 years (95% CI) 14 (11–18)
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Characteristic Patients (n=423)
  % Alive at 5 years (95% CI) 10 (7–13)
Abbreviations: n, number; WBC, white blood cell count.
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